Novartis gets green light for new Afinitor use in EU - Pharma Times PDF Print
Pharma Times
Novartis' oral anticancer drug Afinitor has been approved in the EU for the treatment of pancreatic neuroendocrine tumours, adding to its existing indication in renal cell carcinoma. Afinitor (everolimus) has been cleared for unresectable or metastatic ...
Novartis drug Afinitor® gains EU approval to treat patients with advanced

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.